Since their introduction in 2004, drug-coated balloons (DCBs) have emerged as a novel technology for improving percutaneous coronary intervention (PCI) outcomes by mitigating revascularisation, in-stent restenosis, and associated major adverse cardiac events (MACE) (1). DCBs function by locally delivering antiproliferative drugs to the vessel wall during balloon inflation via semi-compliant balloon. An excipient on the DCB aids in retaining the drug on the balloon during transit, enhancing the drug’s adherence to the vessel wall, and improves the deposition of the drug in the tissue. Paclitaxel and sirolimus are commonly used drugs that prevent smooth muscle proliferation, minimize endothelial dysfunction and neoatherosclerosis. Their lipophilic nature facilitates quick absorption by cells and homogenous distribution, resulting in a sustained impact on smooth muscle cells.
Author Sub-editor: Dr Pok-Tin Tang Dr Pok-Tin Tang is an ST5 cardiology registrar in the Thames Valley deanery, currently undertaking a period of out of
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Joshua Rowland Dr Joshua Rowland is a cardiology registrar working in the North West Deanery. He graduated from the University of Manchester
Author Sub-editor: Dr Atmadeep Banerjee Dr Atmadeep Banerjee is an ST4 Cardiology Registrar in the Kent, Surrey and Sussex deanery. He graduated from Calcutta National
